Age, gender, and racial differences in incidence and survival in primary CNS lymphoma

Abstract

Background:Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma that accounts for ∼4% of newly diagnosed central nervous system (CNS) tumours. The objective of this study was to analyse the epidemiology, incidence, and outcome of these rare tumours.Methods:Primary brain and CNS lymphoma cases were identified from the Surveillance, Epidemiology, and End Results (SEER) research data sets for the years 1980–2008 for analysis of trends in incidence and survival. SEER*Stat v. 7.0.4 software was used to analyse the data.Results:The overall incidence rate of PCNSL was 0.47 per 100 000 person-years. The incidence was significantly higher in males compared with females, blacks aged 0–49 years at diagnosis compared with whites, and whites aged 50 years and older at diagnosis compared with blacks. After a significant decline in incidence between 1995 and 1999, incidence rates rose slightly; those aged 75+ years at diagnosis had the most dramatic increase in incidence rates over time. Five-year survival rates were significantly higher in whites compared with blacks aged 0–49 years at diagnosis, but was primarily driven by white women aged 0–49 years.Conclusion:There is an increase in incidence of PCNSL in the elderly, and elderly blacks have lower incidence compared with white population. Survival remains poor and is negatively dominated by factors associated with HIV infection and advanced age.

Primary intramedullary spinal cord lymphoma: a population-based study

“…However, when compared with literature in the context of primary CNS lymphomas, our patient demographics are consistent with existing reports. 21,22 The histological type of PISCL in this study consisted mainly of B-cell origin lymphoma, and the most prevalent overall lymphoma is diffuse large B-cell lymphoma, …”

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group

“…Incidence has increased during the last decades, particularly in elderly patients. 1,2 Median age at diagnosis has increased from 60.5 to 65 years during the last 20 years. 3 In 2002, the Nordic Lymphoma Group published a phase ll trial investigating whether an age-adjusted regimen consisting of chemotherapy alone could induce durable remissions in PCNSL patients.…”

Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience

“…Primary central nervous system lymphoma (PCNSL) is a predominantly extranodal non-Hodgkin's B-cell lymphoma (NHL) of the brain, spinal cord, leptomeninges and eyes, with an incidence of 0.47 cases per 100,000 person-years (1). Traditional therapies for systemic NHL, such as the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen, have proven to be ineffective in PCNSL, presumably due to poor drug penetration across the blood-brain barrier (BBB) (2).…”